Jane Street Group LLC Sells 33,398 Shares of Immunome, Inc. (NASDAQ:IMNM)

Jane Street Group LLC lessened its stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 64.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,153 shares of the company's stock after selling 33,398 shares during the quarter. Jane Street Group LLC's holdings in Immunome were worth $193,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Northern Trust Corp raised its position in Immunome by 9.1% in the 4th quarter. Northern Trust Corp now owns 516,491 shares of the company's stock valued at $5,485,000 after buying an additional 43,146 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Immunome by 14.2% in the 4th quarter. The Manufacturers Life Insurance Company now owns 189,060 shares of the company's stock worth $2,008,000 after acquiring an additional 23,569 shares in the last quarter. Aquatic Capital Management LLC purchased a new stake in shares of Immunome in the fourth quarter valued at about $95,000. Adage Capital Partners GP L.L.C. lifted its position in shares of Immunome by 127.3% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 500,000 shares of the company's stock valued at $5,310,000 after purchasing an additional 280,000 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Immunome by 12.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,282,754 shares of the company's stock valued at $24,243,000 after purchasing an additional 246,447 shares in the last quarter. Hedge funds and other institutional investors own 44.58% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on IMNM shares. Lifesci Capital initiated coverage on shares of Immunome in a research report on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 price objective for the company. Wall Street Zen upgraded Immunome from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Guggenheim decreased their price target on Immunome from $35.00 to $25.00 and set a "buy" rating for the company in a research report on Thursday, March 20th. Stephens reiterated an "overweight" rating and set a $30.00 price target on shares of Immunome in a report on Thursday, March 20th. Finally, Wedbush reissued an "outperform" rating and issued a $21.00 price objective (down previously from $33.00) on shares of Immunome in a research report on Tuesday, May 13th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Immunome has a consensus rating of "Moderate Buy" and a consensus target price of $23.33.

Insider Buying and Selling at Immunome

In other Immunome news, CTO Philip Tsai bought 12,300 shares of Immunome stock in a transaction dated Monday, March 24th. The stock was purchased at an average price of $8.42 per share, for a total transaction of $103,566.00. Following the completion of the purchase, the chief technology officer now directly owns 33,300 shares of the company's stock, valued at approximately $280,386. This trade represents a 58.57% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Clay B. Siegall purchased 137,100 shares of the stock in a transaction dated Wednesday, March 26th. The stock was acquired at an average cost of $7.29 per share, for a total transaction of $999,459.00. Following the transaction, the chief executive officer now owns 806,736 shares of the company's stock, valued at approximately $5,881,105.44. This trade represents a 20.47% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 161,400 shares of company stock valued at $1,207,395. Company insiders own 8.60% of the company's stock.

Immunome Stock Performance

IMNM stock traded up $0.30 during mid-day trading on Tuesday, hitting $9.57. The company had a trading volume of 619,394 shares, compared to its average volume of 917,812. The firm has a market cap of $832.70 million, a PE ratio of -1.18 and a beta of 1.94. Immunome, Inc. has a 12 month low of $5.15 and a 12 month high of $16.81. The stock's fifty day moving average price is $7.99 and its two-hundred day moving average price is $9.50.

Immunome (NASDAQ:IMNM - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.14. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The company had revenue of $2.93 million during the quarter, compared to analyst estimates of $0.46 million. Equities analysts anticipate that Immunome, Inc. will post -2.21 earnings per share for the current year.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.